Clinical Trial Search

Primary: Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point…

Primary: Narcotic Usage — 997.7; 1025.8 morphine equivalents

Primary: Transfer Performance (TAI Scores Part 1) — 6.31; 9.92 units on a scale

Primary: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE During Treatment Phase (TP) and Follow-up Phase (FP) — 18; 15…

Primary: Time From Spinal Administration to Block Regression to the S1 Dermatome in Post-Anesthesia Care Unit (PACU) — 203; 195; 156; 159 minutes

Primary: Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 — 18.5 percentage of participants

Primary: Percent Repigmentation — 48.5; 2.5 Percent Repigmentation

Primary: Side Effect of Cadaveric Donor Liver NK Cell Infusion — 0; 0 participants

Primary: Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I) — 1; 1; 2; 0 participants

Primary: Progression Free Survival — 4.8; 6.8 months — p=0.0583

Primary: Overall Response Rate — 0 patients

Primary: Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density — 0.042; 0.008; 0.047 g/cm2

Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone — 6…